Yoshihisa Toda
Overview
Explore the profile of Yoshihisa Toda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fukumoto A, Tajima K, Hori M, Toda Y, Kaku S, Matsumoto H
J Pharm Pharmacol
. 2018 Apr;
70(7):929-936.
PMID: 29607510
Objectives: We developed S (+)-flurbiprofen plaster (SFPP), a novel NSAID patch containing S (+)-flurbiprofen (SFP), a potent cyclooxygenase (COX) inhibitor. The purpose of this study was to assess efficacy of...
2.
Sugimoto M, Toda Y, Hori M, Mitani A, Ichihara T, Sekine S, et al.
Drug Dev Res
. 2016 Jun;
77(4):206-11.
PMID: 27241582
Preclinical Research The aim of this study was to evaluate the efficacy of multiple applications of S(+)-flurbiprofen plaster (SFPP), a novel Nonsteroidal anti-inflammatory drug (NSAID) patch, for the alleviation of...
3.
Sugimoto M, Toda Y, Hori M, Mitani A, Ichihara T, Sekine S, et al.
Drug Dev Res
. 2016 Jan;
77(1):20-8.
PMID: 26763139
Preclinical Research This article describes the properties of a novel topical NSAID (Nonsteroidal anti-inflammatory drug) patch, SFPP (S(+)-flurbiprofen plaster), containing the potent cyclooxygenase (COX) inhibitor, S(+)-flurbiprofen (SFP). The present studies...
4.
Murakami S, Sakurai T, Toda Y, Morito A, Sakono M, Fukuda N
Vascul Pharmacol
. 2010 Aug;
53(3-4):177-84.
PMID: 20674770
The sulfur-containing amino acid, taurine, has been shown to ameliorate the vascular disorders. We examined the effects of taurine ingestion on intimal thickening following balloon injury. Balloon injury was induced...
5.
New cyclic tetrapeptides from Nonomuraea sp. TA-0426 that inhibit glycine transporter type 1 (GlyT1)
Terui Y, Chu Y, Li J, Ando T, Fukunaga T, Aoki T, et al.
Bioorg Med Chem Lett
. 2008 Nov;
18(24):6321-3.
PMID: 19013063
In the course of our search for natural antipsychotic agents, we isolated five new cyclic tetrapeptides from the fermentation broth of Nonomuraea sp. TA-0426. These compounds turned out to be...
6.
Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, et al.
Bioorg Med Chem
. 2007 Nov;
16(3):1111-24.
PMID: 18006322
In this study, a novel series of CB(2) receptor agonist imine derivatives, 1-6, was synthesized and evaluated for activity against the CB(2) receptor. In a previous paper we reported the...
7.
Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, et al.
Bioorg Med Chem Lett
. 2007 Sep;
17(22):6299-304.
PMID: 17884496
A novel series of N-alkylidenearylcarboxamides 4, a CB(2) receptor agonist, were synthesized and evaluated for activity against the human CB(2) receptor. In a previous paper, we reported that sulfonamide derivative...
8.
Ohta H, Ishizaka T, Yoshinaga M, Morita A, Tomishima Y, Toda Y, et al.
Bioorg Med Chem Lett
. 2007 Jul;
17(18):5133-5.
PMID: 17643986
A novel series of sulfonamide derivatives 3, the CB(2) receptor agonists, was synthesized and evaluated for activity against the human CB(2) receptor. We first identified sulfonamide 3a, which was obtained...
9.
Yamano Y, Yoshioka M, Toda Y, Oshida Y, Chaki S, Hamamoto K, et al.
J Vet Med Sci
. 2004 Dec;
66(11):1323-7.
PMID: 15585943
We investigated the effects of electrical foot shock stress on the melanocortin signaling cascade and the hypothalamus-pituitary-adrenal (HPA) system by observing levels of mRNA expression of corticotropin releasing factor (CRF),...
10.
Isokawa K, Sejima H, Shimizu O, Yamazaki Y, Yamamoto K, Toda Y
Anat Rec A Discov Mol Cell Evol Biol
. 2004 Jul;
279(2):708-19.
PMID: 15278941
In this study, a unique fiber system in the subectodermal mesenchyme of the chick limb bud was visualized immunohistochemically with the use of a novel monoclonal antibody termed "FB1." This...